Advanced Malignant Solid Tumor
Conditions
Keywords
EGFR, IL10, Advanced Malignant Solid Tumor
Brief summary
This is a Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
Detailed description
The study includes three phases: dose escalation (Phase Ia), dose extension (Phase Ib), and clinical exploration (Phase IIa).First, the Phase Ia dose escalation will be carried out. After finishing the Phase 1a dose escalation, the Phase Ib dose extension study can be carried out in the MTD dose which is obtained from Phase 1a . After Phase Ia &1b are completed and RP2D is obtained, Phase IIa clinical exploratory research can be carried out.
Interventions
DRUGIAE0972
IAE0972 is an investigational product
Sponsors
SUNHO（China）BioPharmaceutical CO., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Ability to provide informed consent and documentation of informed consent prior to initiation of any study-related tests or procedures that are not part of standard of care for the patient's disease. Patients must also be willing and able to comply with study procedures, including the acquisition of specified research specimens. 2\. Male or female, of any race, aged between 18 years and 80 years; 3. With histologically or cytologically confirmed locally advanced or metastatic solid malignant tumors, either refractory to standard therapy or for which no effective therapy was available. 4\. Measurable disease as determined by RECIST version 1.1 and documented by computed tomography (CT) and/or magnetic resonance imaging (MRI). 5\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 6. Life expectancy ≥ 12 weeks. 7. Resolution of all chemotherapy or radiation-related toxicities to ≤ Grade 1 (with exception of ≤ Grade 2 alopecia, stable sensory neuropathy, or stable electrolyte disturbances that are managed by supplementation). 8\. Acceptable laboratory parameters as follows: 1. Platelet count (PLT) ≥ 90 × 109/L without transfusion within 2 weeks prior to the initiation of investigational product. 2. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L in the absence of any growth factor support within 2 weeks prior to the initiation of investigational product. 3. International normalized ratio of prothrombin time (INR) ≤ 1.5 × upper limit of normal (ULN), activated partial thromboplastin time (APTT) ≤ 1.5 × ULN. 4. Hemoglobin (HGB) ≥ 90 g/L. 5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN; for patients with hepatic metastases, ALT and AST ≤ 5.0 × ULN. 6. Total bilirubin ≤ 1.5 × ULN, except patients with Gilbert's syndrome, who may enroll if the conjugated bilirubin is within normal limits. 7. Serum creatinine \< 1.5 × ULN, or estimated creatinine clearance ≥ 60 mL/min as measured or calculated using the Cockcroft-Gault formula. 9\. Female patients of childbearing potential (not surgically sterilized and between menarche and 1- year postmenopause) must have a negative serum or urine pregnancy test performed within 7 days prior to the initiation of investigational product administration. Further, female patients of childbearing potential must agree to use highly effective contraceptive measures (include hormonal contraceptives, intrauterine device or system, vasectomy, or tubal ligation) from the time of consent through 3 months after discontinuation of investigational product administration. 10\. Male patients with partners of childbearing potential must use barrier contraception. In addition, male patients should also have their partners use another method of contraception from the time of consent through 3 months after discontinuation of investigational product administration.
Exclusion criteria
* 1\. Known hypersensitivity (≥ Grade 3) to recombinant proteins or any excipient contained in the drug or vehicle formulation for IAE0972. 2\. History of another malignancy or a concurrent malignancy. Exceptions include patients who have been disease free for two years, or successfully treated for non-melanoma skin cancer, localized prostate cancer (Gleason Score \< 6) or carcinoma in situ, for example cervical cancer in situ, are eligible. 3\. Treatment with any systemic anti-neoplastic therapy, radiation therapy or investigational therapy within 4 weeks prior to the initiation of investigational product administration, with the following exceptions: 1. Nitrosourea or mitomycin C should be within 6 weeks prior to the initiation of investigational product administration. 2. Oral fluoropyrimidines and small molecule targeted drugs should be within 2 weeks or 5 half-lives (whichever is later) prior to the initiation of investigational product administration. 4\. History of trauma or major surgery within 4 weeks prior to the initiation of investigational product administration. 5\. Treatment with corticosteroids (prednisone ≥ 10 mg per day or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of investigational product administration. Steroids for topical, ophthalmic, inhaled or nasal administration are allowed. 6\. Treatment with immunomodulatory agents, including but not limited to thymosin, interleukin-2 and interferon within 14 days prior to the initiation of investigational product administration. 7\. Vaccination with any live virus vaccine within 4 weeks prior to the initiation of investigational product administration. 8\. History of prior allogeneic bone marrow, stem-cell or solid organ transplantation. 9\. Active brain or leptomeningeal metastases. Patients with brain metastases are eligible if these have been treated and MRI or CT shows no evidence of progression for at least 8 weeks after treatment completion and within 4 weeks prior to the initiation of investigational product. Patients are not eligible if they required high doses of systemic corticosteroids that could result in immunosuppression (\>10 mg/day prednisone equivalents) for at least 2 weeks prior to the initiation of investigational product. 10\. Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of investigational product. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than one week prior to the initiation of investigational product. 11\. Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction (PCR). 12\. Known positive testing for human immunodeficiency virus (HIV) or history of acquired immune deficiency syndrome (AIDS). 13\. Clinically significant pulmonary compromise, including a requirement for supplemental oxygen use to maintain adequate oxygenation. 14\. History of clinically significant cardiovascular disease including but not limited to: <!-- --> 1. Myocardial infarction or unstable angina within the 6 months prior to the initiation of investigational product. 2. Stroke or transient ischemic attack within 6 months prior to the initiation of investigational product. 3. Clinically significant cardiac arrhythmias, or a QTc prolongation to \> 470 millisecond (ms) corrected by Fridericia's method based on a 12-lead electrocardiogram (ECG) in screening. 4. Uncontrolled hypertension: systolic blood pressure (SBP) \>180 mmHg, diastolic blood pressure (DBP) \>100 mmHg. 5. Congestive heart failure (New York Heart Association \[NYHA\] class III-IV). 6. Pericarditis or clinically significant pericardial effusion. 7. Myocarditis. 8. Left ventricle ejection fraction (LVEF) \< 50% by echocardiogram. 15. Any history of known or suspected autoimmune disease with the specific exceptions of vitiligo, resolved childhood atopic dermatitis, psoriasis not requiring systemic treatment (within the past 2 years), and patients with a history of autoimmune disease that are now clinically stable with replacement therapy and by laboratory testing. 16\. History of ≥ grade 3 immune-related adverse events (irAE) or Grade 2 immune-associated myocarditis accompanied with immunotherapy. 17\. Clinically uncontrolled effusion in the third space. 18. Known alcohol or drug dependence. 19. Dementia or altered mental status that would preclude understanding and rendering of informed consent. 20\. The female patient who is pregnant or breastfeeding, or expecting to conceive, AND the male patient who is expecting to father children within the projected duration of the trial, starting with the screening visit through 90 days after the last dose of trial treatment. 21\. Any issue that in the opinion of the investigator, would contraindicate the patient's participation in the study or confound the results of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety and tolerability of IAE0972 in Phase I | 28 days after last medication, an average of 1 year | MTD/R2PD ,Incidence and frequency of DTL; AE，SAE occurrence and frequency (according to NCI CTCAE 5.0) |
| Objective response rate (ORR) in Phase IIa | Baeline until disease progression, assessed up to 36 months | To explore the effectiveness of IAE0972. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetic (PK) Css,min | after multiple doses , an average of 1 year | PK parameters Css,min following multiple doses |
| Pharmacokinetic (PK) Css,av | after multiple doses , an average of 1 year | PK parameters Css,av following multiple doses |
| Pharmacokinetic (PK) AUCss | after multiple doses , an average of 1 year | PK parameters AUCss following multiple doses |
| Pharmacokinetic (PK) CLss | after multiple doses , an average of 1 year | PK parameters CLss following multiple doses |
| Pharmacokinetic (PK) Vss | after multiple doses , an average of 1 year | PK parameters Vss following multiple doses |
| Pharmacokinetic (PK) R | after multiple doses , an average of 1 year | PK parameters R following multiple doses |
| Pharmacokinetic (PK) DF | after multiple doses , an average of 1 year | PK parameters DF following multiple doses |
| Pharmacokinetic (PK) Cmin | after single dose , an average of 1 year | PK parameters Cmin following single dose |
| Pharmacokinetic (PK) Tmax | after single dose , an average of 1 year | PK parameters Tmax following single dose |
| Pharmacokinetic (PK) AUC0-t | after single dose , an average of 1 year | PK parameters AUC0-t following single dose |
| Pharmacokinetic (PK) AUC0-∞ | after single dose , an average of 1 year | PK parameters AUC0-∞ following single dose |
| Pharmacokinetic (PK) CL | after single dose , an average of 1 year | PK parameters CL following single dose |
| Pharmacokinetic (PK) Cmax | after single dose , an average of 1 year | PK parameters Cmax following single dose |
| Pharmacokinetic (PK) t1/2 | after single dose , an average of 1 year | PK parameters t1/2 following single dose |
| Pharmacokinetic (PK) λz | after single dose , an average of 1 year | PK parameters λz following single dose |
| Objective response rate (ORR) (Phase I ) | Baeline until disease progression or death, an average of 1 year | To explore the preliminary effectiveness of IAE0972. |
| Overall survival (OS) (Phase I ) | Baeline until disease progression or death, an average of 1 year | To explore the preliminary effectiveness of IAE0972. |
| Disease control rate (DCR) (Phase I ) | Baeline until disease progression or death, an average of 1 year | To explore the preliminary effectiveness of IAE0972. |
| To evaluate the Immunogenicity of IAE0972 in patients with advanced malignant solid tumors (Phase I ) | Before each administration of dose cycle，an average of 1 year | The frequency of anti-drug antibodies(ADA) against IAE0972 |
| Progression-free survival（PFS) in Phase II | Baeline until disease progression or death,assessed up to 36 months | To explore the effectiveness of IAE0972. |
| Overall survival (OS)in Phase II | Baeline until disease progression or death,assessed up to 36 months | To explore the effectiveness of IAE0972. |
| Disease control rate (DCR) in Phase II | Baeline until disease progression or death,assessed up to 36 months | To explore the effectiveness of IAE0972. |
| Immunogenicity of IAE0972 (Phase II ) | Before each administration of dose cycle,assessed up to 36 months | The frequency of anti-drug antibodies(ADA) against IAE0972 |
| Incidence of adverse event (AEs) and SAEs (Phase II) | After last medication,assessed up to 36 months | To investigate the safety characteristics |
| Pharmacokinetic (PK) Vd | after single dose , an average of 1 year | PK parameters Vd following single dose |
| Pharmacokinetic (PK) Css,max | after multiple doses , an average of 1 year | PK parameters Css,max following multiple doses |
Countries
China
Contacts
Primary ContactMinwei Manager
Outcome results
None listed